Vestal Point Capital, LP 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Vestal Point Capital, LP disclosed 75 US equity positions worth $2.7bn in its Q4 2025 13F filing. The largest position was ABVX at 9.4% of the reported book, followed by ACLXGBX and 430. Against the Q3 2025 filing, it opened 12 new positions, added to 21 and reduced 14 among the top 50 holdings.
What did Vestal Point Capital, LP own in Q4 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ABVX Abivax SA | 9.4% | $256.2m | 1,900,000 | 90% | added | |
| 2 | ACLXGBX Arcellx Inc | 7.0% | $190.7m | 2,925,000 | 134% | added | |
| 3 | 430 Terns Pharmaceuticals Inc | 6.7% | $181.8m | 4,500,000 | – | new | |
| 4 | BMRN BioMarin Pharmaceutical Inc | Healthcare | 6.5% | $178.3m | 3,000,000 | 261% | added |
| 5 | GMED Globus Medical Inc | Healthcare | 4.1% | $111.3m | 1,275,000 | 2% | added |
| 6 | NRIX Nurix Therapeutics Inc | Healthcare | 3.3% | $89.0m | 4,690,000 | 35% | added |
| 7 | ALC Alcon AG | Healthcare | 3.2% | $87.1m | 1,105,000 | 0% | held |
| 8 | DXCM Dexcom Inc | Healthcare | 3.1% | $84.6m | 1,275,000 | 96% | added |
| 9 | MRK Merck & Co Inc | Healthcare | 3.0% | $81.6m | 775,000 | – | new |
| 10 | TSHA Taysha Gene Therapies Inc | Healthcare | 2.8% | $75.6m | 13,750,000 | 150% | added |
| 11 | ABT Abbott Laboratories | Healthcare | 2.8% | $75.2m | 600,000 | 140% | added |
| 12 | IMTX Immatics NV | Healthcare | 2.4% | $64.3m | 6,125,000 | -4% | reduced |
| 13 | TYRA Tyra Biosciences Inc | Healthcare | 2.3% | $63.8m | 2,425,000 | 0% | held |
| 14 | BCAX Bicara Therapeutics Inc | 2.2% | $60.2m | 3,575,000 | -30% | reduced | |
| 15 | ARWR Arrowhead Pharmaceuticals Inc | Healthcare | 2.2% | $59.8m | 900,000 | – | new |
| 16 | ELVN Enliven Therapeutics Inc | Healthcare | 2.2% | $59.0m | 3,830,000 | 230% | added |
| 17 | IRON Disc Medicine Inc | Healthcare | 2.1% | $58.4m | 735,000 | 47% | added |
| 18 | JAZZ Jazz Pharmaceuticals PLC | Healthcare | 1.8% | $49.3m | 290,000 | -42% | reduced |
| 19 | DAWNGBX Day One Biopharmaceuticals Inc | 1.8% | $48.5m | 5,200,000 | 94% | added | |
| 20 | LXEO Lexeo Therapeutics Inc | Healthcare | 1.6% | $44.4m | 4,475,000 | 38% | added |
| 21 | ANRO Alto Neuroscience Inc | Healthcare | 1.6% | $44.2m | 2,485,000 | 162% | added |
| 22 | APGE Apogee Therapeutics Inc | Healthcare | 1.5% | $41.5m | 550,000 | 29% | added |
| 23 | OLMA Olema Pharmaceuticals Inc | Healthcare | 1.5% | $41.2m | 1,650,000 | – | new |
| 24 | AXSM Axsome Therapeutics Inc | Healthcare | 1.4% | $38.4m | 210,000 | 40% | added |
| 25 | ASND Ascendis Pharma A/S | Healthcare | 1.4% | $37.3m | 175,000 | -71% | reduced |
| 26 | RAPP Rapport Therapeutics Inc | 1.2% | $33.7m | 1,110,000 | 17% | added | |
| 27 | SLDB Solid Biosciences Inc | Healthcare | 1.2% | $32.8m | 5,815,000 | 95% | added |
| 28 | CLDX Celldex Therapeutics Inc | Healthcare | 1.2% | $31.6m | 1,165,000 | -3% | reduced |
| 29 | SRRK Scholar Rock Holding Corp | Healthcare | 1.1% | $30.8m | 700,000 | -53% | reduced |
| 30 | 4XC1 KalVista Pharmaceuticals Inc | 1.1% | $30.5m | 1,890,000 | 152% | added | |
| 31 | VERA Vera Therapeutics Inc | Healthcare | 1.0% | $27.9m | 550,000 | -28% | reduced |
| 32 | XENE Xenon Pharmaceuticals Inc | Healthcare | 1.0% | $26.9m | 600,000 | -45% | reduced |
| 33 | LNTH Lantheus Holdings Inc | Healthcare | 0.9% | $24.0m | 360,000 | 112% | added |
| 34 | RVMD Revolution Medicines Inc | Healthcare | 0.9% | $23.5m | 295,000 | -53% | reduced |
| 35 | ZYME Zymeworks Inc | Healthcare | 0.8% | $22.8m | 865,000 | -51% | reduced |
| 36 | IMCR Immunocore Holdings PLC | Healthcare | 0.7% | $20.3m | 585,000 | – | new |
| 37 | UPB Upstream Bio Inc | 0.7% | $19.5m | 720,000 | – | new | |
| 38 | BBNX Beta Bionics Inc | Healthcare | 0.7% | $18.3m | 600,000 | 0% | held |
| 39 | CBIO Crescent Biopharma Inc | 0.7% | $17.8m | 1,500,000 | – | new | |
| 40 | BCRX BioCryst Pharmaceuticals Inc | Healthcare | 0.6% | $17.6m | 2,250,000 | – | new |
| 41 | PEN Penumbra Inc | Healthcare | 0.6% | $15.5m | 50,000 | – | new |
| 42 | GERN Geron Corp | Healthcare | 0.5% | $14.9m | 11,320,000 | -34% | reduced |
| 43 | RGEN Repligen Corp | Healthcare | 0.5% | $13.6m | 83,000 | -79% | reduced |
| 44 | ZBH Zimmer Biomet Holdings Inc | Healthcare | 0.5% | $13.5m | 150,000 | – | new |
| 45 | BMY Bristol-Myers Squibb Co | Healthcare | 0.5% | $13.5m | 250,000 | – | new |
| 46 | GLUE Monte Rosa Therapeutics Inc | 0.4% | $12.2m | 775,000 | -3% | reduced | |
| 47 | FULC Fulcrum Therapeutics Inc | Healthcare | 0.4% | $10.7m | 950,000 | – | new |
| 48 | SVRA Savara Inc | Healthcare | 0.4% | $9.7m | 1,606,000 | -60% | reduced |
| 49 | Engene Holdings Inc | 0.3% | $9.5m | 1,055,000 | 185% | added | |
| 50 | AGIO Agios Pharmaceuticals Inc | Healthcare | 0.3% | $8.8m | 325,000 | 156% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.